BlackRock Inc. Purchases Shares of 4,990,181 Oruka Therapeutics, Inc. $ORKA

Key Points

• BlackRock acquired 4.99 million shares of Oruka Therapeutics during the second quarter, worth approximately $474.9 million and representing an 8.27% stake. Institutional investors collectively own 56.44% of the company.
• Oruka shares opened at $102.42, near their 52-week high of $115.51, while the company reported a quarterly loss of $0.55 per share—worse than analysts’ $0.51 estimate.
• Analysts remain broadly bullish, with a “Moderate Buy” consensus and an average price target of $134.30; however, insiders sold 83,116 shares worth $6.64 million over the past three months.

BlackRock Inc. purchased a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,990,181 shares of the company's stock, valued at approximately $474,916,000. BlackRock Inc. owned about 8.27% of Oruka Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. Viking Global Investors LP bought a new position in Oruka Therapeutics during the third quarter valued at $51,280,000. Deep Track Capital LP grew its position in Oruka Therapeutics by 38.4% during the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company's stock worth $51,051,000 after purchasing an additional 735,983 shares during the last quarter. Vanguard Group Inc. raised its stake in Oruka Therapeutics by 38.1% in the 4th quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company's stock worth $74,366,000 after acquiring an additional 676,865 shares during the last quarter. RTW Investments LP raised its stake in shares of Oruka Therapeutics by 5.8% in the fourth quarter. RTW Investments LP now owns 2,058,148 shares of the company's stock worth $62,382,000 after purchasing an additional 112,499 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP acquired a new stake in Oruka Therapeutics during the 4th quarter valued at approximately $51,840,000. 56.44% of the stock is owned by institutional investors.

Oruka Therapeutics Stock Performance

Shares of ORKA opened at $102.42 on Tuesday. Oruka Therapeutics, Inc. has a 1 year low of $14.34 and a 1 year high of $115.51. The stock has a market capitalization of $6.78 billion, a PE ratio of -50.45 and a beta of -0.34. The stock has a 50-day simple moving average of $92.49 and a 200-day simple moving average of $65.93.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). Analysts predict that Oruka Therapeutics, Inc. will post -2.27 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Piper Sandler reaffirmed an "overweight" rating and set a $180.00 target price on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Barclays upped their price target on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the stock an "overweight" rating in a research report on Monday, April 27th. BTIG Research restated a "buy" rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Guggenheim restated a "buy" rating and set a $200.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Finally, Wedbush reissued an "outperform" rating and issued a $165.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $134.30.

Insider Activity at Oruka Therapeutics

In other news, Director Carl Dambkowski sold 22,417 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $70.13, for a total value of $1,572,104.21. Following the completion of the sale, the director directly owned 51,326 shares of the company's stock, valued at approximately $3,599,492.38. This represents a 30.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,000 shares of the firm's stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the transaction, the senior vice president directly owned 15,312 shares in the company, valued at $1,633,177.92. The trade was a 39.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 83,116 shares of company stock worth $6,636,533. Insiders own 23.49% of the company's stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source